Sort   by:  
 Page size 
UnknownEffect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study.
Not available
S-EPMC4171746 | biostudies-literature
UnknownImpact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Not available
S-EPMC5054930 | biostudies-literature
UnknownDeveloping a questionnaire to evaluate an automated audit & feedback intervention: a Rand-modified Delphi method.
Not available
S-EPMC10998400 | biostudies-literature
UnknownTrends in the epidemiology of depression and comorbidities from 2000 to 2019 in Belgium.
Not available
S-EPMC9241171 | biostudies-literature
UnknownImpact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
Not available
S-EPMC4662806 | biostudies-literature
UnknownRapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Not available
S-EPMC3003523 | biostudies-literature
UnknownBlended care to discontinue benzodiazepine receptor agonists use in patients with chronic insomnia disorder: a pragmatic cluster randomized controlled trial in primary care.
Not available
S-EPMC10091092 | biostudies-literature
UnknownEffectiveness of a blended care programme for the discontinuation of benzodiazepine use for sleeping problems in primary care: study protocol of a cluster randomised trial, the Big Bird trial.
Not available
S-EPMC7045121 | biostudies-literature
UnknownEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Not available
S-EPMC3888598 | biostudies-literature
Sort   by:  
 Page size